OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 22, Issue SUPPL.3, 2007, Pages

  Horl W H ^a   Macdougall, I C ^b   Rossert, J ^c   Schaefer, R M ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35548930650     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm014     Document Type: Article

References (33)

1. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 [Suppl 2]: ii1-ii47.
2. Galloway MJ, Smellie WS. Investigating iron status in microcytic anaemia. Br Med J 2006; 791-793
3. Hörl WH, Cavill I, Macdougall IC, Schaefer RM, Sunder-Plassmann G. How to diagnose and correct iron deficiency during r-huEPO therapy-a consensus report. Nephrol Dial Transplant 1996; 11: 246-250
4. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006; 47 [Suppl 3]: S11-S145
5. Tarng DC, Huang TP. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant 1998; 13: 2867-2872
6. Hörl WH. Is there a role for adjuvant therapy in patients being treated with epoetin? Nephrol Dial Transplant 1999; 14 [Suppl 2]: 50-60
7. Keven K, Kutlay S, Nergizogly G, Ertürk S. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 2003; 41: 1233-1239
8. Schaefer RM, Schaefer L. Hypochromic red blood cells and reticulocytes. Kidney Int 1999; 55 [Suppl 69]: S44-S48
9. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001; 60: 2406-2411
10. Tsuchiya K, Okano H, Teramura M et al. Content of reticulocyte hemoglobin is a reliable tool for determining iron deficiency in dialysis patients. Clin Nephrol 2003; 59: 115-123
11. Brugnara C, Schiller B, Moran J. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol 2006; 28: 303-308
12. Cullen P, Söffker J, Höpfl M et al. Hypochromic red cells and reticulocyte haemglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis. Nephrol Dial Transplant 1999; 14: 659-665
13. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation 1999; 68: 391-396
14. Hörl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007; 18: 382-393
15. Fachinformation: CosmoFer GRY-Pharma GmbH, Juni 2001
16. Fachinformation: Ferrlecit Aventis Pharma Deutschland GmbH, Dezember 2001
17. Fachinformation: Venofer Fresenius Medical Care Deutschland GmbH, Juni 1999
18. Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001; 16: 1239-1244
19. Agarwal R, Vasavada N, Sachs NG et al. Oxidative stress in renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289
20. Macdougall IC, Roche A. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis 2005; 46: 283-289
21. Leehey DJ, Palubiak DJ, Chebrrolu S, Agarwal R. Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study. Nephrol Dial Transplant 2005; 20: 135-140
22. Aronoff GR, Bennett WM, Blumenthal S et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 2004; 66: 1193-1198
23. Lorenz M, Kletzmayr J, Perschl A, Furrer A, Hörl WH, Sunder-Plassmann G. Anaemia and iron deficiencies among long-term renal transplant recipients. J Am Soc Nephrol 2002; 13: 794-797
24. Macdougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-1699
25. Ahsan M. Intravenous infusion of total dose iron is superior to oral iron in treatment of anaemia in peritoneal dialysis patients: a single-center comparative study. J Am Soc Nephrol 1998; 9: 664-668
26. Vychytil A, Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int Suppl 1999; 69: S71-S78
27. Johnson DW, Herzig KA, Gissane R et al. Oral versus intravenous iron supplementation in peritoneal dialysis patients. Perit Dial 2001; 21 [Suppl 3]: S231-S235
28. Van Wyck DB, Roppolo M, Martinez CA et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005; 68: 2846-2856
29. Agarwal R, Rizkala AR, Bastani B et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006; 26: 445-454
30. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001; 38: 988-991
31. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070-2076
32. Besarab A, Amin N, Ahsan M et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-538
33. DeVita MV, Frumkin D, Mittal S et al. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol 2003; 60: 335-340